Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Anisodine Hydrobromide for Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib Dose-Escalation Study

15 de novembro de 2026 atualizado por: The Affiliated Hospital of Xuzhou Medical University

Safety and Tolerability of Anisodine Hydrobromide in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib, Open-Label, Nonrandomized, 3+3 Dose-Escalation Study

This study is an investigator-initiated Phase Ib clinical trial employing a prospective, single-center, open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of anisodine hydrobromide in patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment and to determine the recommended dose for subsequent clinical studies.

Visão geral do estudo

Status

Ainda não está recrutando

Intervenção / Tratamento

Descrição detalhada

This study is an investigator-initiated, prospective, single-center Phase Ib clinical trial designed to evaluate the safety and tolerability of anisodine hydrobromide administered to patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment. The trial adopts an open-label, non-randomized, 3+3 dose-escalation design to identify the maximum tolerated dose (MTD) and determine the recommended Phase II dose (RP2D).

Tipo de estudo

Intervencional

Inscrição (Estimado)

24

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Age 18 to 80 years.
  2. Diagnosis of acute ischemic stroke.
  3. Time from stroke onset to first dose of study medication ≤24 hours.
  4. Imaging-confirmed acute vertebrobasilar artery occlusion (VBAO), including basilar artery occlusion, bilateral intracranial vertebral artery occlusion, or vertebrobasilar tandem occlusion.
  5. Eligible for and planned to undergo emergency endovascular treatment.
  6. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6.
  7. Posterior circulation Alberta Stroke Program Early CT Score (pcASPECTS) ≥6.
  8. No definite extensive irreversible infarction on posterior circulation imaging assessment.
  9. Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  10. Written informed consent obtained from the participant or their legally authorized representative.

Exclusion Criteria:

  1. Evidence of intracranial hemorrhagic disease on head CT, including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.
  2. History of congenital or acquired bleeding disorders, coagulation factor deficiencies, or thrombocytopenic disorders.
  3. Vascular anatomical conditions expected to prevent successful completion of endovascular treatment.
  4. Known severe allergy to iodinated contrast media.
  5. Pregnancy or breastfeeding, or planning to become pregnant during the study period or within 90 days after enrollment.
  6. Known allergy to anisodine hydrobromide or a history of severe intolerance following previous administration.
  7. Concomitant clinical conditions that may be exacerbated by anticholinergic drugs, including but not limited to angle-closure glaucoma, urinary retention, prostatic hypertrophy with difficulty urinating, or paralytic ileus.
  8. Severe cardiac arrhythmias (e.g., tachyarrhythmias requiring electrical cardioversion or recurrent syncope) or hemodynamic instability (e.g., requiring vasopressors or persistent hypotension).
  9. Severe psychiatric disorders, dementia, or impaired consciousness that would prevent the participant from providing informed consent or completing follow-up.
  10. Malignancy or other severe systemic diseases with an expected survival of less than 90 days.
  11. Participation in another interventional clinical study within 30 days before enrollment, or current participation in another interventional clinical study.
  12. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Anisodine Hydrobromide 1.0 mg

Participants receive anisodine hydrobromide 1.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

Experimental: Anisodine Hydrobromide 1.5 mg

Participants receive anisodine hydrobromide 1.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

Experimental: Anisodine Hydrobromide 2.0 mg

Participants receive anisodine hydrobromide 2.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

Experimental: Anisodine Hydrobromide 2.5 mg

Participants receive anisodine hydrobromide 2.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Occurrence of Predefined Safety Events Within 8 Days
Prazo: Within 8 days after the first administration

The primary safety outcome is the occurrence of predefined safety events within 8 consecutive days after the first administration of the study drug. Predefined safety events include: (1) symptomatic intracranial hemorrhage (sICH), defined as intracranial hemorrhage confirmed by neuroimaging in conjunction with neurological deterioration, operationalized as an increase of at least 4 points in the NIHSS score; (2) death from any cause; and (3) any other serious adverse event (SAE), excluding the foregoing events, that is adjudicated by the Data Monitoring Committee (DMC) to be definitely, probably, or possibly related to the study drug.

Within 8 days after the first administration

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Early Neurological Deterioration
Prazo: Within 24 hours after treatment initiation

Early neurological deterioration is defined as worsening in neurological status within 24 hours after treatment initiation. Neurological status is assessed using the National Institutes of Health Stroke Scale (NIHSS), a validated clinical instrument for assessing stroke severity. The NIHSS total score ranges from 0 to 42, with higher scores indicating greater neurological impairment.

Within 24 hours after treatment initiation
Infarct Volume
Prazo: Day 8

Infarct volume measured on non-contrast cranial computed tomography (CT) at Day 8, expressed in milliliters (mL).

Day 8
Functional Outcome (Modified Rankin Scale)
Prazo: Day 90

Functional outcome assessed using the modified Rankin Scale (mRS) at Day 90. The mRS score ranges from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability. The distribution of mRS scores will be reported.

Day 90
Incidence of Symptomatic Intracranial Hemorrhage
Prazo: Within 8 days after the first administration

Incidence of symptomatic intracranial hemorrhage (sICH) confirmed by neuroimaging and accompanied by neurological deterioration, defined as an increase of at least 4 points in the NIHSS score, within 8 days after the first administration of the study drug.

Within 8 days after the first administration
Incidence of Any Intracranial Hemorrhage
Prazo: Within 8 days after the first administration

Incidence of any intracranial hemorrhage detected by neuroimaging within 8 days after the first administration of the study drug, regardless of whether neurological deterioration is present.

Within 8 days after the first administration
Incidence of Study Drug-Related Adverse Events
Prazo: Within 90 days after the first administration

Incidence of adverse events (AEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide.

Within 90 days after the first administration
Incidence of Study Drug-Related Serious Adverse Events
Prazo: Within 90 days after the first administration

Incidence of serious adverse events (SAEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide.

Within 90 days after the first administration
All-Cause Mortality
Prazo: Within 90 days after the first administration

All-cause mortality occurring within 90 days after the first administration of the study drug.

Within 90 days after the first administration

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Yu Feng, MD, PhD, The Affiliated Hospital of Xuzhou Medical University
  • Diretor de estudo: Yanbo Cheng, MD, PhD, The Affiliated Hospital of Xuzhou Medical University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

20 de novembro de 2026

Conclusão Primária (Estimado)

20 de janeiro de 2027

Conclusão do estudo (Estimado)

20 de janeiro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

15 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever